Mobidiag Ltd. has launched Automobi Molecular Diagnostics Co., Ltd, which is a joint venture between Mobidiag and Autobio Diagnostics, one of the leading clinical diagnostics companies in China.

Automobi will be responsible for commercialising Mobidiag's Novodiag^® platform and selected infectious disease assays in the Greater China territory. The Novodiag^® platform combines real-time PCR and microarray technologies, for fully automated, direct  detection of infectious diseases, including antibiotic resistances from samples placed in a disposable cartridge. It also allows for comprehensive screening of multiple or single pathogens within approximately one hour.

Automobi’s initial activities will include the registration of the Novodiag^® platform and first assays with the National Medical Products Administration (NMPA, former CFDA). Automobi will also establish local facilities in China to manufacture certain Novodiag^® components and disposables, for the Greater China territory.

As previously announced in December 2018, Mobidiag and Autobio jointly agreed to invest €12.3m to establish Automobi in China. Autobio is investing €8m in cash to hold 65%, and Mobidiag is investing €4.3m to hold 35%. Under the terms of the partnership, Automobi acquired an exclusive license from Mobidiag to commercialise the Novodiag^® platform and selected human infectious disease assays (excluding sepsis) for China.

In December 2018, Autobio invested €10m in Mobidiag. These funds are being used to grow the Company’s product portfolio, accelerate the development of further assays for the Novodiag^® system and enhance its manufacturing capabilities, as well as to further facilitate Mobidiag’s commercial expansion.